Novartis以Q3的有力结果击败了人们的期望,提出了长期增长目标,并证实尽管存在一般竞争,仍进行了重大投资。 Novartis beat expectations with strong Q3 results, raised long-term growth targets, and confirmed major investments despite generic competition.

Novartis报告第三季度的利润和销售额比预期的要强,净收入增至39.3亿美元,销售额达到139.1亿美元,其驱动力来自Kisqali、Kesimpta和Pluvicto等新药的强劲表现。 Novartis reported stronger-than-expected third-quarter profits and sales, with net income rising to $3.93 billion and sales reaching $13.91 billion, driven by strong performance from newer drugs like Kisqali, Kesimpta, and Pluvicto. 尽管由于非专利竞争,其心脏药物Entresto销售平坦,但该公司重申其2025年的前景,预测高单位数字销售增长和低青少年营业收入增长。 Despite flat sales of its heart drug Entresto due to generic competition, the company reaffirmed its 2025 outlook, projecting high-single-digit sales growth and low-teen operating income growth. 它还在2029年将其长期销售增长目标提高到每年6%,并证实正在进行投资,包括购买120亿美元的美国生物技术稳定,以抵消专利到期。 It also raised its long-term sales growth target to 6% annually through 2029 and confirmed ongoing investments, including a $12 billion acquisition of U.S. biotech Avidity, to offset patent expirations.